M&T Bank Corp Acquires 2,408 Shares of Vertex Pharmaceuticals Incorporated $VRTX

M&T Bank Corp boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 19.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,732 shares of the pharmaceutical company’s stock after acquiring an additional 2,408 shares during the quarter. M&T Bank Corp’s holdings in Vertex Pharmaceuticals were worth $6,679,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Exencial Wealth Advisors LLC lifted its position in Vertex Pharmaceuticals by 1,392.1% in the 4th quarter. Exencial Wealth Advisors LLC now owns 22,382 shares of the pharmaceutical company’s stock valued at $10,147,000 after acquiring an additional 20,882 shares in the last quarter. Quadcap Wealth Management LLC lifted its position in Vertex Pharmaceuticals by 33.9% in the 4th quarter. Quadcap Wealth Management LLC now owns 1,790 shares of the pharmaceutical company’s stock valued at $812,000 after acquiring an additional 453 shares in the last quarter. Eagle Wealth Advisors LLC bought a new position in Vertex Pharmaceuticals in the 4th quarter valued at approximately $325,000. Ashton Thomas Private Wealth LLC lifted its position in Vertex Pharmaceuticals by 3.7% in the 4th quarter. Ashton Thomas Private Wealth LLC now owns 2,503 shares of the pharmaceutical company’s stock valued at $1,135,000 after acquiring an additional 89 shares in the last quarter. Finally, RMR Wealth Builders raised its stake in Vertex Pharmaceuticals by 8.8% during the 4th quarter. RMR Wealth Builders now owns 5,789 shares of the pharmaceutical company’s stock valued at $2,625,000 after buying an additional 466 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Trading Down 1.3%

Shares of VRTX opened at $424.36 on Wednesday. The firm has a market cap of $107.94 billion, a PE ratio of 25.17, a P/E/G ratio of 1.87 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $507.92. The firm has a fifty day simple moving average of $452.77 and a two-hundred day simple moving average of $449.59.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, topping the consensus estimate of $4.24 by $0.23. The firm had revenue of $2.99 billion during the quarter, compared to analyst estimates of $2.99 billion. Vertex Pharmaceuticals had a return on equity of 24.41% and a net margin of 35.51%.Vertex Pharmaceuticals’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business posted $4.06 EPS. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 16.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on VRTX shares. Jefferies Financial Group started coverage on shares of Vertex Pharmaceuticals in a research note on Tuesday, March 10th. They set a “buy” rating and a $580.00 target price for the company. Wolfe Research upgraded shares of Vertex Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $548.00 target price for the company in a research note on Tuesday, January 6th. Bank of America boosted their target price on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Wall Street Zen lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Oppenheimer boosted their target price on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an “outperform” rating in a research note on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $554.83.

Insider Transactions at Vertex Pharmaceuticals

In other news, Director Sangeeta N. Bhatia sold 318 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $423.73, for a total value of $134,746.14. Following the completion of the sale, the director directly owned 4,924 shares in the company, valued at $2,086,446.52. This represents a 6.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joy Liu sold 1,104 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the sale, the executive vice president owned 20,729 shares of the company’s stock, valued at $8,810,239.58. This trade represents a 5.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 81,853 shares of company stock worth $38,479,135 over the last three months. 0.20% of the stock is currently owned by insiders.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat on EPS and showed revenue growth driven by product sales; management highlighted broad portfolio strength and pipeline progress, supporting longer‑term growth thesis. Business Wire: Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Sales of new CF therapies and other recently launched products accelerated, contributing materially to product revenue growth and suggesting multiple near‑term commercial growth engines. Reuters: Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Neutral Sentiment: Vertex reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B), roughly in line with consensus — supportive for guidance stability but not a clear upside catalyst. Investor Slide Deck / Press Release (Q1 2026)
• Neutral Sentiment: Analysts revised models and price targets after the Q1 release — many maintained Outperform/Buy views but trimmed targets, reflecting mixed near‑term readings despite constructive longer‑term views. Benzinga: These Analysts Revise Their Forecasts On Vertex After Q1 Earnings
• Negative Sentiment: Insider selling was reported this week (EVP Joy Liu sold 1,104 shares; director Sangeeta Bhatia sold 318 shares). Trades were executed under 10b5‑1 plans, but active insider sales can weigh on sentiment. SEC Form 4 (Joy Liu) SEC Form 4 (Sangeeta Bhatia)
• Negative Sentiment: Shares dipped after the mixed report (EPS/revenue beats but some metrics and commentary left investors cautious), prompting near‑term profit‑taking and PT trims. Yahoo Finance: Vertex Dips On Mixed First‑Quarter Report

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.